Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back

Carlos A. Morillo (he/him/his)

PROFESSOR
Libin Cardiovascular Institute- Centro Nacional de Investigación Cardiovascular
Cumming School of Medicine, University of Calgary

I am a Professor in the Department of Cardiac Sciences, and Medicine, and Senior Clinician Scientist at the Libin Cardiovascular Institute. I am currently on an Academic Sabbatical at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid, Spain where I am conducting basic science research focused on mechanisms of persistent AF and development on novel AADs. I held the position of Section Chief Cardiology Division at the Libin Cardiovascular Institute, University of Calgary and Zone Head Cardiology for the Calgary & Southeastern Alberta Region, Alberta Health Services, between 2016-2022. My main research interests are related with the development of clinical trials in the area of cardiac arrhythmias, syncope and treatment of Chagas Disease. Similarly, I have made some contributions in Cardiac autonomic regulation, sympathetic nerve traffic and baroreflex modulation in different disease stages such as Sudden Cardiac death, Stroke, and particularly neurally mediated reflex syncope and Chagas cardiomyopathy. I have been directly involved with the design, conduct, reporting and publishing of several landmark trials that have changed practice related with detection of subclinical atrial fibrillation such as the ASSERT and CRYSTAL-AF trials, in addition to conducting the largest randomized trial in Chagas disease (BENEFIT) Trial and exploring bew therapies in Chagas (STOP-CHAGAS) and PARACHUTE-HF trials. I am a member of the executive and steering committees of several atrial fibrillation ablation and Stroke prevention trials such as RAAFT-2, STAR-AF I-III, EARLY-AF, Progressive-AF, AWARE, ACTIVE, RELY, ELIMINATE-AF, PAPS, SPAIN, SPRITELY, VENUS to mention a few. I have also participated in several randomized trials evaluating different therapeutic strategies in neurally mediated syncope including VPS and co-applicant Prevention of Syncope Trials (POST) all funded by CIHR.

Disclosure(s): Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Presentation(s):